Limitations of Experimental Human Abuse Liability ... - immpact

More documents

Recommendations

Info

So what should the primary outcomemeasure be?• In review articles of ALA, drug liking isconsidered one of the most, if not the most,sensitive and reliable measure of abuse liability• Current “problem” is that liking is measured inabuse liability studies in a number of differentways
• BipolarDrug liking– VAS: 0= dislike a lot; 50=neutral; 100=like a lot– Discrete scale:• 1=dislike a lot; 4=neutral; 7=like a lot• -4=dislike a lot; 0=neutral; +4=like a lot• Unipolar– VAS: 0=not at all; 100=extremely– Discrete scale: 0=not at all; 1= a little bit; 2=moderately;3=quite a bit; 4=very much
Page 1 and 2: Limitations of Experimental HumanAb
Page 3 and 4: Issues Relating to Human ALA ofOpio
Page 5 and 6: An Added Component to Traditional A
Page 7 and 8: Major Issues Related ToExtractabili
Page 9 and 10: Extractability (Benchtop) Testing:T
Page 11 and 12: 2. What is the appropriate subject
Page 13 and 14: 2. What is the appropriate subject
Page 15 and 16: 3. When doing IN and IV ALA, should
Page 17 and 18: 3. When doing IN and IV ALA, should
Page 19 and 20: 4. What kind of ALA testing needs t
Page 21 and 22: 5. Latency to peak positive effects
Page 23 and 24: The issue of weighting due to rate
Page 25 and 26: 6. What constitutes a clinically si
Page 27 and 28: 6. What constitutes a clinically si
Page 29 and 30: Does ALA have predictive validity?
Page 31 and 32: Have ALA instruments been validated
Page 33: CPDD Expert Panels recommendation
Page 37: Acknowledgments• Kenzie Preston,

Limitations of Experimental Human Abuse Liability ... - immpact

Create successful ePaper yourself

Delete template?

Save as template?